Experienced in administering high end radiotherapy techniques like 3DCRT, IMRT, VMAT, respiratory gating therapy, IGRT, SRS, SRT, brachytherapy etc
Extensive experience in research in the field of head and neck cancer and breast cancer
Worked with renowned healthcare institutions like Amrita Institute Medical Science, Kerala, Tata Medical Centre, Kolkata, International Oncology Group, Fortis, Noida and Mahavir Cancer Sansthan, Patna.

Publications

Rita R, Singh U, Trivedi V, Chauhan R, Kumari A (2017) Determinants of Survival of Cervical Cancer: A Hospital Based Study. Gynecol Obstet 7: 437. doi:10.4172/2161-0932.1000437.
Chatterjee S, Chakraborty S; HYPORT Adjuvant Author Group. Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)-study protocol for a multicentre, randomized phase III trial. Trials. 2020;21(1):819. Published 2020 Sep 30. doi:10.1186/s13063-020-04751-y
S. Bhusal, S. Chatterjee, S. Chakraborty, A. Kumari, S. Bachianathan, A. Mahato, P. Lal, S. Gupta, P. Solomon, K.M. Das, S. Mandal. PO-1797: Dosimetric analysis of simultaneous integrated boost in the HYPORT Adjuvant Trial (NCT03788213). DOI:10.1016/S0167-8140(21)01815-6. ESTRO 2020 abstract
Ritesh santosham, Sanjoy Chatterjee, Santam Chakraborty, Avipsa Das, Abha Kumari Hypofractionated Radiotherapy with SIB in Advanced Incurable Breast Cancer -HYPORT B study (NCT03669497). DOI:10.13140/RG.2.2.36479.64160, ESTRO 2020 abstract

Area of Interest

Head and Neck cancer
Breast cancer
Gynecological cancer

Clinical Research

Co-investigator in National cancer registry program (NCRP) in Mahavir Cancer Sansthan, Patna
Principal investigator in Quality of life and employment status in head and neck cancer patients from rural area, treated at a tertiary cancer center in tier II city of India: A Prospective cross-sectional study
Co-investigator in a Intensifying radiation treatment in advanced/ poor prognosis laryngeal, hypopharyngeal (LH) and oropharyngeal cancers (OPC) using PET –CT based dose escalation strategies. (INTELHOPE)
Co-investigator in HYPOfractionated Radiation Therapy comparing a standard radiotherapy schedule (over three weeks) with a novel one-week schedule in Adjuvant breast cancer: An open label randomized controlled study (HYPORT- Adjuvant)
Co-Investigator in Hypofractionated Radiotherapy schedule of 26 Gy in 5 fractions with simultaneous integrated boost (6 Gy) in advanced incurable breast cancer: A prospective Phase I/II study.
Co-Investigator in a prospective, multicenter, randomized, double blind, parallel group study to compare the efficacy and safety of biosimilar cetuximab versus innovator cetuximab in combination with platinum-based chemotherapy in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (ALK18/ENZ124-CET1)
Co-investigator in a phase III, double-blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumors (ADD-Aspirin, breast cancer cohort)
Co-investigator in a Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti−PD-L1 Antibody) in Combination with Paclitaxel Compared with Placebo with Paclitaxel for Patients with Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer (MO39196)
Co-investigator in a Phase II, multicenter, open-label, two-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2 – negative advanced breast cancer ( aBC ), who have progressed on or after CDK 4/6 inhibitor treatment (CBYL719X2402)
Co-investigator in a randomized, Double-Blind, Multi-Centre, Parallel Group Study Comparing Two Humanized Monoclonal Antibodies that Target HER2 Receptors in Combination with Weekly Paclitaxel Administered as First-Line Treatment in Patients with HER2-Positive Metastatic Breast Cancer (TZ-01-002)
Co-investigator in a Phase III, Double Blind, Placebo-Controlled, Randomized study of Ipatasertib in combination with Atezolizumab and Paclitaxel As a treatment for patients with Locally Advanced Unresectable or Metastatic Triple – Negative Breast Cancer (CO41101)
Co-investigator in a Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Her2-Positive Breast Cancer at High Risk Of Recurrence Following Preoperative Therapy (WO42633).